Beactica Therapeutics names new head of Preclinical Development and new directors
10 September 2019 -

Beactica Therapeutics, the Swedish drug discovery company, announced yesterday that it has named Vendela Parrow, PhD as its new head of Preclinical Development and Maarten de Chateau and Håkan Wickholm as new directors.

Parrow brings with her extensive experience in preclinical and clinical development from key positions at Akinion Pharmaceuticals, Axelar and Pharmacia Biovitrum. She was a co-founder, CSO and CEO of Akinion with responsibility for the interactions with competent authorities, independent review boards and clinics in several European countries. She is head of facility of In Vitro and Systems Pharmacology Facility at SciLifeLab Drug Discovery and Development Platform.

The company has named Maarten de Chateau and Håkan Wickholm as its new directors. Maarten de Chateau is currently CEO of Sixera Pharma and Buzzard Pharmaceuticals. He serves as chairman of the board of Atrogi, and on the boards of Cavis Technologies and Gesynta Pharma. Maarten was co-founder and CEO of Cormorant Pharmaceuticals. Prior to that, Maarten held the position of medical director at Swedish Orphan Biovitrum; he has also worked in clinical development at Sanofi and as an investment bank financial analyst for five years. Maarten holds a PhD and an MD from the University of Lund, Sweden. Hakan Wickholm has 30 years of experience in international strategy formulation, business development and commercialisation. Besides his engagement in Beactica he serves on the board of Genovis. Hakan has held senior positions in international pharmaceutical and biotech companies, including CBO and CEO of Lytix Biopharma and various management positions in AstraZeneca.